Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H.

Mov Disord. 2011 Oct;26(12):2190-5. doi: 10.1002/mds.23806.

2.

Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis.

Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, Rosen AR, Zabetian CP, Payami H.

J Neurol Neurosurg Psychiatry. 2011 May;82(5):564-8. doi: 10.1136/jnnp.2010.222042.

3.

Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease.

Wang G, Huang Y, Chen W, Chen S, Wang Y, Xiao Q, Liu J, Fung VS, Halliday G, Chen S.

Parkinsonism Relat Disord. 2016 Mar;24:89-94. doi: 10.1016/j.parkreldis.2015.12.018.

PMID:
26776090
4.

Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease.

Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S, Infante J, Garcia-Gorostiaga I, Sierra M, Combarros O, Snapinn KW, Edwards KL, Zabetian CP.

Mov Disord. 2011 Apr;26(5):819-23. doi: 10.1002/mds.23642.

5.

Genetic substrates of psychosis in patients with Parkinson's disease: A critical review.

Lenka A, Arumugham SS, Christopher R, Pal PK.

J Neurol Sci. 2016 May 15;364:33-41. doi: 10.1016/j.jns.2016.03.005. Review.

PMID:
27084212
6.

[Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].

Kashihara K, Ohno M, Katsu Y.

Rinsho Shinkeigaku. 2005 Jan;45(1):1-5. Japanese.

PMID:
15714992
7.

Exploring gene-environment interactions in Parkinson's disease.

McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H.

Hum Genet. 2008 Apr;123(3):257-65. doi: 10.1007/s00439-008-0466-z.

PMID:
18210157
8.

Survival in Parkinson's disease. Relation with motor and non-motor features.

de Lau LM, Verbaan D, Marinus J, van Hilten JJ.

Parkinsonism Relat Disord. 2014 Jun;20(6):613-6. doi: 10.1016/j.parkreldis.2014.02.030.

PMID:
24679900
9.

Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.

Feldman B, Chapman J, Korczyn AD.

Acta Neurol Scand. 2006 Jan;113(1):14-7.

PMID:
16367893
10.

[ApoE polymorphisms and dopaminergic replacement therapy in Parkinson's disease].

Cervantes-Arriaga A, Rodríguez-Violante M, González-Latapí P, Dávila-Ortiz de Montellano DJ, Yescas P, Alonso-Vilatela E.

Rev Med Inst Mex Seguro Soc. 2014 Jan-Feb;52(1):14-8. Spanish.

PMID:
24625478
11.

Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.

Huang Y, Rowe DB, Halliday GM.

J Parkinsons Dis. 2011;1(3):271-6. doi: 10.3233/JPD-2011-11027.

PMID:
23939307
12.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946.

13.

A 12-year population-based study of freezing of gait in Parkinson's disease.

Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G.

Parkinsonism Relat Disord. 2015 Mar;21(3):254-8. doi: 10.1016/j.parkreldis.2014.12.020.

PMID:
25603767
14.

Nonmotor Symptoms and Cognitive Decline in de novo Parkinson's Disease.

Kwon KY, Kang SH, Kim M, Lee HM, Jang JW, Kim JY, Lee SM, Koh SB.

Can J Neurol Sci. 2014 Sep;41(5):597-602. doi: 10.1017/cjn.2014.3.

PMID:
25373810
15.

Nonmotor complications in Parkinson's disease.

Adler CH.

Mov Disord. 2005;20 Suppl 11:S23-9. Review.

PMID:
15822106
16.

Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression.

Morgante L, Colosimo C, Antonini A, Marconi R, Meco G, Pederzoli M, Pontieri FE, Cicarelli G, Abbruzzese G, Zappulla S, Ramat S, Manfredi M, Bottacchi E, Abrignani M, Berardelli A, Cozzolino A, Paradiso C, De Gaspari D, Morgante F, Barone P; PRIAMO Study Group..

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):76-82. doi: 10.1136/jnnp-2011-300043.

PMID:
21836035
17.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

18.

Clinical phenotype of drug-naïve Parkinson's disease based on nonmotor symptoms.

Lee HM, Lee SS, Kim M, Kang SH, Seo WK, Kim JH, Koh SB.

Arch Gerontol Geriatr. 2015 Nov-Dec;61(3):517-22. doi: 10.1016/j.archger.2015.07.001.

PMID:
26183203
19.
20.

Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.

Baumann CR, Held U, Valko PO, Wienecke M, Waldvogel D.

Mov Disord. 2014 Feb;29(2):207-13. doi: 10.1002/mds.25650.

PMID:
24105646

Supplemental Content

Support Center